nach oben

03.05.2024 | Research

Treatment, healthcare utilization and outcomes in patients with glioblastoma in Ontario: a 10-year cohort study

verfasst von: Wafa Baqri, Kathryn Rzadki, Steven Habbous, Sunit Das

Erschienen in: Journal of Neuro-Oncology

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Glioblastoma (GBM) is the most common malignant primary brain tumour in adults. Receipt of adjuvant therapies has been shown to exert a significant positive effect on patient survival. Little is known however about how changes in standards of care and healthcare system factors, such as access, affect real-world outcomes. In this study, we provide an overview of GBM in Ontario and examine elements of care, including treatment patterns, healthcare utilization, and overall survival, from 2010 to 2019, to interpret the impact of the changes in practice standards and expansion of the care network within this period.

Methods

Using linked health-administrative databases from Ontario, Canada, we conducted a population-based cohort study to examine the clinical and biological characteristics, treatment, and healthcare utilization patterns of adult GBM patients diagnosed between 2010 and 2019. The primary outcomes were enrollment in adjuvant chemoradiation treatment and 1-, 2-, and 5-year survival. All analyses were performed using the Statistical Analysis Software (SAS).

Results

5392 patients were diagnosed with GBM in Ontario from 2010 to 2019 (58% male, 42% female). The median age at diagnosis was 64. Receipt of adjuvant chemoradiation within one year of diagnosis increased from 51% in 2010 to 63% in 2019. 1-year, 2-year, and 5-year overall survival for all patients remained stable, ranging between 40 and 43%, 15–19%, and 5–7%, respectively. For patients above the age of 65, however, 1-year survival increased from 19% in 2010 to 26% in 2019.

Interpretation

Regionalization enabled access to treatment closer to home for many patients. Over the last decade, receipt of adjuvant chemoradiation increased among elderly patients, but the improvement in 1-year overall survival over time was accounted for by sociodemographic and clinical covariates. Our findings support the efforts for regionalization of services to improve accessibility.

Conclusion

This Ontario-based study provides insight into the effect of practice evolution and healthcare utilization on the overall survival of patients with GBM. Overall survival for most patients with glioblastoma has remained stagnant over the past decade. Changes in treatment standards and expansion of access to treating centres have been associated with prolonged survival in elderly glioblastoma patients.

Nur mit Berechtigung zugänglich

Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1CrossRefPubMed

Ostrom QT, Cioffi G, Gittleman H et al (2019) CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2012–2016. Neuro Oncol 21(Suppl 5):v1–v100. https://doi.org/10.1093/neuonc/noz150CrossRefPubMedPubMedCentral

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330CrossRefPubMed

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. https://doi.org/10.1016/S1470-2045(09)70025-7CrossRefPubMed

Mauer M, Stupp R, Taphoorn MJ et al (2007) The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC brain Tumour and Radiation Oncology groups, and NCIC Clinical Trials Group study. Br J Cancer 97(3):302–307. https://doi.org/10.1038/sj.bjc.6603876CrossRefPubMedPubMedCentral

Bottomley A, Vanvoorden V, Flechtner H, Therasse P, EORTC Quality of Life Group EORTC Data Center (2003) The challenges and achievements involved in implementing quality of life research in cancer clinical trials. Eur J Cancer 39(3):275–285. https://doi.org/10.1016/s0959-8049(02)00729-3CrossRefPubMed

Perry JR, Laperriere N, O’Callaghan CJ et al (2017) Short-course Radiation plus Temozolomide in Elderly patients with Glioblastoma. N Engl J Med 376(11):1027–1037. https://doi.org/10.1056/NEJMoa1611977CrossRefPubMed

Pollom EL, Sborov KD, Soltys SG, Asch SM, Sudore RL, Aslakson RA (2018) Advance Care Planning needs in patients with Glioblastoma Undergoing Radiotherapy. J Pain Symptom Manage 56(6):e6–e8. https://doi.org/10.1016/j.jpainsymman.2018.08.021CrossRefPubMedPubMedCentral

Hendren S, Chin N, Fisher S et al (2011) Patients’ barriers to receipt of cancer care, and factors associated with needing more assistance from a patient navigator. J Natl Med Assoc 103(8):701–710. https://doi.org/10.1016/s0027-9684(15)30409-0CrossRefPubMed

10.

Williams M, Treasure P, Greenberg D, Brodbelt A, Collins P (2016) Surgeon volume and 30 day mortality for brain tumours in England. Br J Cancer 115(11):1379–1382. https://doi.org/10.1038/bjc.2016.317CrossRefPubMedPubMedCentral

11.

Barker FG 2nd, Curry WT Jr, Carter BS (2005) Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care. Neuro Oncol 7(1):49–63. https://doi.org/10.1215/S1152851704000146CrossRefPubMedPubMedCentral

12.

Walker EV, Davis FG (2019) CBTR founding affiliates. Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013. Neuro Oncol 21(3):360–369. https://doi.org/10.1093/neuonc/noy195CrossRefPubMedPubMedCentral

13.

Weerasinghe A, Smith CR, Majpruz V et al (2018) Validity of administrative databases in comparison to medical charts for breast Cancer Treatment Data. J Cancer Epidemiol 2018:9218595. https://doi.org/10.1155/2018/9218595CrossRefPubMedPubMedCentral

14.

Statistics Canada Tables 17-10-0134-01 Population estimates, July 1, by health region and peer group, 2018 boundaries. https://doi.org/10.25318/1710013401-eng

15.

Voisin MR, Sasikumar S, Mansouri A, Zadeh G (2021) Incidence and prevalence of primary malignant brain tumours in Canada from 1992 to 2017: an epidemiologic study. CMAJ Open 9(4):E973–E979. https://doi.org/10.9778/cmajo.20200295CrossRefPubMedPubMedCentral

16.

Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P et al (2020) Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. J Neurooncol 147(2):297–307. https://doi.org/10.1007/s11060-020-03451-6CrossRefPubMed

17.

Raphael MJ, Siemens DR, Booth CM (2019) Would regionalization of systemic Cancer Therapy improve the quality of Cancer Care? J Oncol Pract 15(7):349–356. https://doi.org/10.1200/JOP.18.00671CrossRefPubMed

18.

Lopez Ramos C, Brandel MG, Steinberg JA et al (2019) The impact of traveling distance and hospital volume on post-surgical outcomes for patients with glioblastoma. J Neurooncol 141(1):159–166. https://doi.org/10.1007/s11060-018-03022-wCrossRefPubMed

19.

Longo CJ, Fitch M, Deber RB, Williams AP (2006) Financial and family burden associated with cancer treatment in Ontario, Canada. Support Care Cancer 14(11):1077–1085. https://doi.org/10.1007/s00520-006-0088-8CrossRefPubMed

20.

Smets T, Lawson TM, Grandin C, Jankovski A, Raftopoulos C (2013) Immediate post-operative MRI suggestive of the site and timing of glioblastoma recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol 23(6):1467–1477. https://doi.org/10.1007/s00330-012-2762-1CrossRefPubMed

21.

Tamimi AF, Juweid M Epidemiology and outcome of Glioblastoma. In: De Vleeschouwer S (ed) Glioblastoma. Brisbane (AU): Codon; September 27, 2017

22.

Holdhoff M, Ye X, Blakeley JO et al (2012) Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol 110(2):279–285. https://doi.org/10.1007/s11060-012-0968-3CrossRefPubMed

23.

Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812. https://doi.org/10.1126/science.1164382CrossRefPubMedPubMedCentral

24.

Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S (2005) A population-based description of glioblastoma multiforme in Los Angeles County, 1974–1999. Cancer 104(12):2798–2806. https://doi.org/10.1002/cncr.21539CrossRefPubMed

25.

Mackillop WJ, Zhang-Salomons J, Groome PA, Paszat L, Holowaty E (1997) Socioeconomic status and cancer survival in Ontario. J Clin Oncol 15(4):1680–1689. https://doi.org/10.1200/JCO.1997.15.4.1680CrossRefPubMed

26.

Porter AB, Lachance DH, Johnson DR (2015) Socioeconomic status and glioblastoma risk: a population-based analysis. Cancer Causes Control 26(2):179–185. https://doi.org/10.1007/s10552-014-0496-xCrossRefPubMed

27.

Kasl RA, Brinson PR, Chambless LB (2016) Socioeconomic status does not affect prognosis in patients with glioblastoma multiforme. Surg Neurol Int.;7(Suppl 11):S282-S290. Published 2016 May 6. https://doi.org/10.4103/2152-7806.181985

28.

Gorey KM, Luginaah IN, Bartfay E et al (2011) Effects of socioeconomic status on colon cancer treatment accessibility and survival in Toronto, Ontario, and San Francisco, California, 1996–2006. Am J Public Health 101(1):112–119. https://doi.org/10.2105/AJPH.2009.173112CrossRefPubMedPubMedCentral

29.

Kovic B, Xie F (2015) Economic evaluation of Bevacizumab for the First-Line treatment of newly diagnosed Glioblastoma Multiforme. J Clin Oncol 33(20):2296–2302. https://doi.org/10.1200/JCO.2014.59.7245CrossRefPubMed

30.

Henriksson R, Asklund T, Poulsen HS (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 104(3):639–646. https://doi.org/10.1007/s11060-011-0565-xCrossRefPubMedPubMedCentral

31.

Ng JCH, See AAQ, Ang TY, Tan LYR, Ang BT, King NKK (2019) Effects of surgery on neurocognitive function in patients with glioma: a meta-analysis of immediate post-operative and long-term follow-up neurocognitive outcomes. J Neurooncol 141(1):167–182. https://doi.org/10.1007/s11060-018-03023-9CrossRefPubMed

32.

Satoer D, Vork J, Visch-Brink E, Smits M, Dirven C, Vincent A (2012) Cognitive functioning early after surgery of gliomas in eloquent areas. J Neurosurg 117(5):831–838. https://doi.org/10.3171/2012.7.JNS12263CrossRefPubMed

33.

Lee J, Park SH, Kim YZ (2018) Prognostic evaluation of neurological Assessment of the Neuro-Oncology Scale in Glioblastoma patients. Brain Tumor Res Treat 6(1):22–30. https://doi.org/10.14791/btrt.2018.6.e1CrossRefPubMedPubMedCentral

34.

Armstrong TS, Vera-Bolanos E, Gning I et al (2011) The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. Cancer 117(14):3222–3228. https://doi.org/10.1002/cncr.25892CrossRefPubMed

35.

Lien K, Zeng L, Nguyen J et al (2011) FACT-Br for assessment of quality of life in patients receiving treatment for brain metastases: a literature review. Expert Rev Pharmacoecon Outcomes Res 11(6):701–708. https://doi.org/10.1586/erp.11.67CrossRefPubMed

Titel: Treatment, healthcare utilization and outcomes in patients with glioblastoma in Ontario: a 10-year cohort study
verfasst von: Wafa Baqri
Kathryn Rzadki
Steven Habbous
Sunit Das
Publikationsdatum: 03.05.2024
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-024-04690-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen